{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:10:39Z","timestamp":1788282639770,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1494,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a paucity of veterinary literature on the safety or outcome of zoledronic acid (ZA) use in dogs for either bone pain or hypercalcemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>The primary aim was to report the adverse events in dogs receiving intravenous administration of ZA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Ninety-five dogs with ZA use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was performed; all dogs that received at least 1 dose of ZA and had a serum biochemistry profile performed before and after treatment were reviewed. Diagnosis, indication for treatment, adverse events and survival times were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-five dogs met the inclusion criteria. Thirty-one (33%) received multiple intravenous infusions of ZA (range, 2-7), making a total of 166 administrations in all dogs. The dose range was 0.13 to 0.32\u2009mg\/kg, given at intervals of 4 to 6\u2009weeks. Thirteen adverse events were recorded in 10 dogs: azotemia (n\u00a0=\u00a08), vomiting (n\u00a0=\u00a02), pancreatitis (n\u00a0=\u00a01), cutaneous ulceration (n\u00a0=\u00a01), and diarrhea (n\u00a0=\u00a01). Zoledronic acid could not be confirmed as the cause of azotemia in any case. The change in serum creatinine concentration from dose to dose was not related to the total dose received (P\u00a0=\u2009.46). Five dogs (5%) changed Veterinary Comparative Oncology Group Common Terminology Criteria (VCOG-CTAE) renal\/genitourinary grade after administration of ZA; their total dose 0.4\u00a0mg\/kg (range, 0.26-0.66) was not significantly different to the group which did not change VCOG-CTAE renal\/genitourinary grade 0.35\u2009mg\/kg (range, 0.2-1.50; P\u00a0=\u2009.93).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Multiple doses of ZA were well tolerated in dogs within this study. A small number of dogs developed progressive azotemia which was not associated with cumulative dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16335","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T05:35:10Z","timestamp":1638509710000},"page":"253-258","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Toxicity of zoledronic acid after intravenous administration: A retrospective study of 95 dogs"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0515-8048","authenticated-orcid":false,"given":"David John","family":"Brewer","sequence":"first","affiliation":[{"name":"Fitzpatrick Referrals Oncology and Soft Tissue , Surrey,","place":["United Kingdom"]},{"name":"Small Animal Teaching Hospital, Leahurst, University of Liverpool , Neston,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Macfarlane","sequence":"additional","affiliation":[{"name":"Fitzpatrick Referrals Oncology and Soft Tissue , Surrey,","place":["United Kingdom"]},{"name":"North Downs Specialist Referrals (NDSR) , Bletchingley,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"O'Connell","sequence":"additional","affiliation":[{"name":"Small Animal Teaching Hospital, Leahurst, University of Liverpool , Neston,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Bacon","sequence":"additional","affiliation":[{"name":"Fitzpatrick Referrals Oncology and Soft Tissue , Surrey,","place":["United Kingdom"]},{"name":"University of Surrey School of Veterinary Medicine , Surrey,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"issue":"1","key":"2026020303503448800_jvim16335-bib-0001","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0002","article-title":"Evaluation of zoledronate as a treatment for hypercalcemia in four dogs","volume":"54","author":"Scheck","year":"2018","journal-title":"J Am Anim Hosp Assoc"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1748-5827.2008.00635.x","article-title":"Zoledronic acid for the treatment of appendicular osteosarcoma in a dog","volume":"50","author":"Spugnini","year":"2009","journal-title":"J Small Anim Pract"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0004","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1939-1676.2005.tb02790.x","article-title":"Fan TM bone metabolic effects of single dose zoledronate in healthy dogs","volume":"19","author":"Lorimier","year":"2005","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0005","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/SPC.0000000000000048","article-title":"Bone cancer pain: from mechanism to therapy","volume":"8","author":"Mantyh","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0007","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2165\/00003495-200464110-00004","article-title":"Zoledronic acid: a review of its use in patients with metastatic cancer","volume":"64","author":"Perry","year":"2004","journal-title":"Drugs"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0008","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0009","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease: treatment of newly diagnosed multiple myeloma: an international, double blinded, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0010","first-page":"524","article-title":"Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model","volume":"4","author":"McDermott","year":"2006","journal-title":"J Support Oncol"},{"key":"2026020303503448800_jvim16335-bib-0011","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1939-1676.2008.0046.x","article-title":"The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis","volume":"22","author":"Fan","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0012","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/jvim.13980","article-title":"Zoledronate\u2014associated osteonecrosis of the jaw in a dog with appendicular osteosarcoma","volume":"30","author":"Lundberg","year":"2016","journal-title":"J Vet Intern Med"},{"key":"2026020303503448800_jvim16335-bib-0013","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0014","first-page":"417","article-title":"Veterinary cooperative oncology group\u2014common terminology certain for adverse events (VCOG-CTAE) follow chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"2026020303503448800_jvim16335-bib-0015","article-title":"IRIS Staging of CKD","author":"International Renal Interest Society (IRIS)","year":"2009"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0016","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/DAD.0000000000000341","article-title":"Zoledronic acid induced interface dermatitis","volume":"37","author":"Succaria","year":"2015","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0017","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2460\/javma.238.2.195","article-title":"Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006)","volume":"238","author":"Saam","year":"2011","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"2026020303503448800_jvim16335-bib-0018","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/vco.12533","article-title":"Auranofin improves overall survival when combined with standard of care in a pilot involving dogs with osteosarcoma","volume":"18","author":"Endo-Munoz","year":"2020","journal-title":"Vet Comp Oncol"},{"key":"2026020303503448800_jvim16335-bib-0019","article-title":"IRIS Grading of AKI","author":"International Renal Interest Society (IRIS)","year":"2016"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16335","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/36\/1\/253\/66666181\/jvim16335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/36\/1\/253\/66666181\/jvim16335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:50:46Z","timestamp":1770108646000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/36\/1\/253\/8449063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16335","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2022,1,1]]},"assertion":[{"value":"2021-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}